<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00370617</url>
  </required_header>
  <id_info>
    <org_study_id>METVIRAL</org_study_id>
    <nct_id>NCT00370617</nct_id>
  </id_info>
  <brief_title>Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance</brief_title>
  <official_title>An Efficacy and Safety Study Comparing Pegylated-Interferon and Ribavirin Plus Metformin to Pegylated-Interferon and Ribavirin in the Treatment of naïve Patients With Genotype 1 Chronic HCV Infection and Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Turin, Italy</source>
  <brief_summary>
    <textblock>
      Chronic hepatitis C virus (HCV) infection is associated with an increased risk for the&#xD;
      development of type 2 diabetes and HCV infection itself may promote insulin resistance,&#xD;
      irrespective of the severity of liver disease.&#xD;
&#xD;
      Insulin resistance seems to be genotype specific and may play a role in fibrogenesis in&#xD;
      chronic hepatitis C.&#xD;
&#xD;
      In an &quot;in vitro&quot; model, increased levels of insulin may promote increased HCV replication.&#xD;
&#xD;
      RATIONALE Decreased insulin resistance and reduced hyperinsulinemia may facilitate the&#xD;
      efficacy of anti-viral drugs on HCV replication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis C virus (HCV) infection is associated with an increased risk for the&#xD;
      development of type 2 diabetes and HCV infection itself may promote insulin resistance,&#xD;
      irrespective of the severity of liver disease.&#xD;
&#xD;
        -  In patients with HCV infection, an increase in fasting insulin levels is associated with&#xD;
           the presence of serum HCV core, the severity of hepatic fibrosis and a decrease in&#xD;
           expression of insulin receptor substrate (IRS) 1 and IRS2, central molecules of the&#xD;
           insulin-signaling cascade. Down-regulation of IRS1 and IRS2 has also been observed in&#xD;
           HCV core-transgenic mice livers and HCV core-transfected human hepatoma cells.&#xD;
&#xD;
        -  High levels of tumor necrosis factor-alpha, which acts by disturbing tyrosine&#xD;
           phosphorylation of insulin receptor substrate-1, may be associated with insulin&#xD;
           resistance both in animal models and in HCV patients.&#xD;
&#xD;
      Insulin resistance seems to be genotype specific and may play a role in fibrogenesis in&#xD;
      chronic hepatitis C.&#xD;
&#xD;
        -  In patients infected with genotype non-3, insulin resistance is associated with the&#xD;
           degree of fibrosis, the rate of fibrosis progression and previous failed antiviral&#xD;
           treatment.&#xD;
&#xD;
        -  Insulin resistance, fibrosis, and genotype are independent predictors of the response to&#xD;
           antiviral therapy in chronic hepatitis C patients treated with peginterferon plus&#xD;
           ribavirin. A sustained virological response is achieved in 33% of patients with genotype&#xD;
           1 and insulin resistance compared with 60% of genotype 1 patients without insulin&#xD;
           resistance.&#xD;
&#xD;
        -  Insulin resistance is associated with a 3-fold risk of failure to antiviral treatment in&#xD;
           patients with genotype 1 In an &quot;in vitro&quot; model, increased levels of insulin may promote&#xD;
           increased HCV replication.&#xD;
&#xD;
      RATIONALE Decreased insulin resistance and reduced hyperinsulinemia may facilitate the&#xD;
      efficacy of anti-viral drugs on HCV replication.&#xD;
&#xD;
      INDICATION Genotype 1 Chronic HCV hepatitis (CHC) associated with insulin resistance (IR).&#xD;
&#xD;
      OBJECTIVES To compare the efficacy and safety of Pegylated-Interferon and Ribavirin plus&#xD;
      metformin to Pegylated-Interferon and Ribavirin for treatment of naïve patients with Genotype&#xD;
      1 Chronic HCV infection and insulin resistance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2006</start_date>
  <completion_date>January 2009</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined end-point of non-detectable serum HCV-RNA (&lt;100 copies/mL) and</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>normal serum ALT activity at the end of the 24 week treatment-free follow up period</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>End-of-treatment virological and biochemical response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained virological and biochemical response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-of-treatment improvement of insulin resistance</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-of-treatment improvement of liver histology</measure>
  </secondary_outcome>
  <enrollment>200</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Insulin Resistance</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. No previous antiviral treatment&#xD;
&#xD;
          2. Persistently elevated alanine aminotransferase (ALT) and quantifiable HCV-RNA (&gt;2000&#xD;
             copies/ml)&#xD;
&#xD;
          3. Liver biopsy (within 12 months) consistent with CHC with or without cirrhosis&#xD;
&#xD;
          4. Compensated liver disease (Child-Pugh grade A)&#xD;
&#xD;
          5. Insulin resistance (evaluated by HOMA-R and OGTT)&#xD;
&#xD;
          6. Negative pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 2 Diabetes (according to ADA criteria)&#xD;
&#xD;
          2. BMI &gt; 30&#xD;
&#xD;
          3. Alcohol consumption &gt; 30 g/day&#xD;
&#xD;
          4. Other forms of liver disease (HBV, autoimmune, genetic), HIV infection.&#xD;
&#xD;
          5. Anemia&#xD;
&#xD;
          6. Psychiatric disease&#xD;
&#xD;
          7. Thyroid disease poorly controlled&#xD;
&#xD;
          8. Overt cirrhosis, hepatocellular carcinoma&#xD;
&#xD;
          9. Significant cardiac, renal, pulmonary disease, seizures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Rizzetto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Torino</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mario Rizzetto, MD</last_name>
    <phone>+39-011-6336397</phone>
    <email>mrizzetto@molinette.piemonte.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabetta Bugianesi, MD</last_name>
    <phone>+39-011-6336397</phone>
    <email>ebugianesi@yahoo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Gastroenterology, University of Torino, Ospedale San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Rizzetto, MD</last_name>
      <phone>+39-011-6336397</phone>
      <email>mrizzetto@molinette.piemonte.it</email>
    </contact>
    <contact_backup>
      <last_name>Elisabetta Bugianesi, MD</last_name>
      <phone>+39-011-6336397</phone>
      <email>ebugianesi@yahoo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Elisabetta Bugianesi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-De-Rueda P, López-Serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-Extremera A, Suárez E, Castillo J. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005 Mar;128(3):636-41.</citation>
    <PMID>15765399</PMID>
  </reference>
  <verification_date>November 2006</verification_date>
  <study_first_submitted>August 30, 2006</study_first_submitted>
  <study_first_submitted_qc>August 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2006</study_first_posted>
  <last_update_submitted>November 13, 2006</last_update_submitted>
  <last_update_submitted_qc>November 13, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2006</last_update_posted>
  <keyword>chronic hepatitis C</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

